AbbVie Stakes $335M on a Startup’s RNAi Drugs

AbbVie stakes $335M on a startup’s RNAi drugs

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer.

AbbVie and ADARx Pharmaceuticals Announce Collaboration

NORTH CHICAGO, Ill. and SAN DIEGO, May 14, 2025 /PRNewswire/ — AbbVie and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, today announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology. siRNA represents a class of molecules capable of regulating gene exp…

AbbVie and ADARx to develop siRNA therapeutics

Under the agreement terms, AbbVie will pay ADARx an upfront of $335m, and the latter is also said to be qualified for additional payments. These include option-related fees, The post AbbVie and ADARx to develop siRNA therapeutics for multiple disease areas appeared first on Pharmaceutical Business review.

AbbVie expands siRNA push with $335m ADARx deal - Pharmaceutical Technology

This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics in 2024.

HAYA Therapeutics, SA, a biotechnology company pioneering precise RNA-guided regulatory genome-targeting therapeutics that reprogram disease-causing cellular states for rare, common, chronic, and age-related diseases, announced...

AbbVie and ADARx Join Forces to Advance Next-Generation siRNA Therapies

The new partnership brings RNA-targeted innovation to dermatology-relevant disease areas like autoimmunity and cancer.